Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2020 Feb 10;20(1):116.
doi: 10.1186/s12879-020-4838-x.

Viscerotropic disease and acute uveitis following yellow fever vaccination: a case report

Lev Volkov  1 , Gilda Grard  2   3 , Pierre-Edouard Bollaert  4 , Guillaume A Durand  2   3 , Aurélie Cravoisy  4 , Marie Conrad  4 , Lionel Nace  4 , Guilhem Courte  4 , Rémy Marnai  4 , Isabelle Leparc-Goffart  2   3 , Sébastien Gibot  4
Affiliations
Case Reports

Viscerotropic disease and acute uveitis following yellow fever vaccination: a case report

Lev Volkov et al. BMC Infect Dis. .

Abstract

Background: Yellow fever vaccine exists for over 80 years and is considered to be relatively safe. However, in rare cases it can produce serious neurotropic and viscerotropic complications. We report a case of a patient who presented both viscerotropic and neurological manifestations after yellow fever vaccination.

Case presentation: We describe the case of a 37 years old man who developed after the yellow fever vaccination a yellow fever vaccine-associated viscerotropic disease followed by acute uveitis. Prolonged detection of yellow fever RNA in blood and urine was consistent with yellow fever vaccine-associated adverse event. The final outcome was good, although with persistent fatigue over a few months.

Conclusions: Even if the yellow fever vaccine is relatively safe, physicians should be aware of its possible serious adverse effects.

Keywords: Uveitis; Yellow fever vaccine; Yellow fever vaccine-associated viscerotropic disease.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Cutaneo-mucous manifestations. a Thoraco-abdominal skin rash. b Strawberry tongue. c Lower limbs skin rash
Fig. 2
Fig. 2
Biological timelines for YFV RNA detection and YFV antibodies response in plasma and urine samples
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Staples JE, Gershman M, Fischer M, Centers for Disease Control and Prevention (CDC) Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep Morb Mortal Wkly Rep Recomm Rep. 2010;59(RR-7):1–27. - PubMed
    1. Monath TP, Vasconcelos PFC. Yellow fever. J Clin Virol Off Publ Pan Am Soc Clin Virol. 2015;64:160–173. doi: 10.1016/j.jcv.2014.08.030. - DOI - PubMed
    1. Theiler M, Smith HH. The use of yellow fever virus modified by in vitro cultivation for human immunization. J Exp Med. 1937;65(6):787–800. doi: 10.1084/jem.65.6.787. - DOI - PMC - PubMed
    1. Monath TP. Yellow fever vaccine. Expert Rev Vaccines. 2005;4(4):553–574. doi: 10.1586/14760584.4.4.553. - DOI - PubMed
    1. Escadafal C, et al. Rapid molecular assays for the detection of yellow fever virus in low-resource settings. PLoS Negl Trop Dis. 2014;8(3):e2730. doi: 10.1371/journal.pntd.0002730. - DOI - PMC - PubMed

Publication types

MeSH terms